Table 1.
First cohort PDTOs
| PDTO ID | Primary tumor or liver met | RAS mutational status | Treatment received before surgery |
|---|---|---|---|
| CR01 | Primary tumor | Mutant | FOLFOX plus bevacizumab |
| CR02 | Primary tumor/liver metastasis | Wild type | No treatment |
| CR03 | Liver metastasis | Mutant | No treatment |
| CR04 | Liver metastasis | Wild type | FOLFOX |
| CR05 | Primary tumor | Unknown | No treatment |
| CR06 | Liver metastasis | Wild type | FOLFOX plus panitumumab |
| CR07 | Liver metastasis | Wild type | No treatment |
| CR08 | Primary tumor | Wild type | No treatment |
| CR09 | Liver metastasis | Wild type | FOLFOX plus cetuximab |
| CR10 | Liver metastasis | Unknown | No treatment |
| CR11 | Liver metastasis | Wild type | FOLFOX plus cetuximab |
| CR12 | Liver metastasis | Wild type | FOLFIRI plus panitumumab |
| CR13 | Liver metastasis | Mutant | No treatment |
| CR14 | Liver metastasis | Mutant | FOLFOX |
| CR15 | Liver metastasis | Mutant | FOLFOX plus bevacizumab |
| CR16 | Primary tumor | Unknown | No treatment |
| CR17 | Liver metastasis | Wild type | FOLFOX |
| CR18 | Liver metastasis | Wild type | FOLFIRI plus cetuximab |
| CR19 | Liver metastasis | Wild type | No treatment |
| CR20 | Liver metastasis | Wild type | FOLFOX plus bevacizumab |
| CR21 | Liver metastasis | Wild type | FOLFIRI plus panitumumab |
| CR22 | Liver metastasis | Mutant | XELOX plus bevacizumab |
| CR23 | Liver metastasis | Mutant | FOLFOXIRI plus bevacizumab |
| CR24 | Liver metastasis | Mutant | FOLFOX |
| CR25 | Liver metastasis | Wild type | No treatment |
| CR26 | Liver metastasis | Mutant | FOLFOX plus bevacizumab |
| CR27 | Liver metastasis | Mutant | XELOX plus bevacizumab |
| CR28 | Liver metastasis | Wild type | FOLFIRI plus panitumumab |
| CR29 | Liver metastasis | Mutant | FOLFOX plus bevacizumab |
| CR30 | Liver metastasis | Wild type | Adjuvant XELOX |
| CR31 | Liver metastasis | Wild type | FOLFIRI plus panitumumab |
FOLFOX, 5-fluorouracil plus oxaliplatin; FOLFIRI, 5-fluorouracil plus irinotecan; FOLFOXIRI, 5-fluorouracilplus oxaliplatin plus irinotecan; PDTO, patient-derived tumor organoid.